MRNA vs. UNH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MRNA and UNH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MRNA | UNH |
|---|---|---|
| Company Name | Moderna, Inc. | UnitedHealth Group Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 9.70 billion USD | 295.51 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | December 7, 2018 | October 17, 1984 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MRNA and UNH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MRNA | UNH |
|---|---|---|
| 5-Day Price Return | 0.04% | 0.09% |
| 13-Week Price Return | -11.60% | 5.87% |
| 26-Week Price Return | -2.82% | 3.37% |
| 52-Week Price Return | -41.22% | -46.88% |
| Month-to-Date Return | -8.80% | -5.77% |
| Year-to-Date Return | -40.43% | -36.37% |
| 10-Day Avg. Volume | 11.56M | 9.12M |
| 3-Month Avg. Volume | 10.45M | 13.84M |
| 3-Month Volatility | 59.86% | 37.81% |
| Beta | 1.20 | 0.44 |
Profitability
Return on Equity (TTM)
MRNA
-31.40%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
MRNA has a negative Return on Equity of -31.40%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
UNH
18.60%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
In the upper quartile for the Health Care Providers & Services industry, UNH’s Return on Equity of 18.60% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
MRNA
-139.61%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
MRNA has a negative Net Profit Margin of -139.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
UNH
4.04%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
UNH’s Net Profit Margin of 4.04% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
MRNA
-155.15%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
MRNA has a negative Operating Profit Margin of -155.15%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
UNH
6.03%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
UNH’s Operating Profit Margin of 6.03% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | MRNA | UNH |
|---|---|---|
| Return on Equity (TTM) | -31.40% | 18.60% |
| Return on Assets (TTM) | -24.44% | 5.71% |
| Net Profit Margin (TTM) | -139.61% | 4.04% |
| Operating Profit Margin (TTM) | -155.15% | 6.03% |
| Gross Profit Margin (TTM) | 63.49% | -- |
Financial Strength
Current Ratio (MRQ)
MRNA
3.93
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
UNH
0.95
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
UNH’s Current Ratio of 0.95 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MRNA
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UNH
0.84
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
UNH’s Debt-to-Equity Ratio of 0.84 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
Interest Coverage Ratio data for MRNA is currently unavailable.
UNH
6.14
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
UNH’s Interest Coverage Ratio of 6.14 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | MRNA | UNH |
|---|---|---|
| Current Ratio (MRQ) | 3.93 | 0.95 |
| Quick Ratio (MRQ) | 3.40 | 0.75 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.84 |
| Interest Coverage Ratio (TTM) | -- | 6.14 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
UNH
2.67%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.67%, UNH offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
UNH
44.61%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
UNH’s Dividend Payout Ratio of 44.61% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | MRNA | UNH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.67% |
| Dividend Payout Ratio (TTM) | 0.00% | 44.61% |
Valuation
Price-to-Earnings Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for MRNA is currently unavailable.
UNH
16.74
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
UNH’s P/E Ratio of 16.74 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
MRNA
4.30
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 4.30 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
UNH
0.68
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
UNH’s P/S Ratio of 0.68 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
MRNA
1.08
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
MRNA’s P/B Ratio of 1.08 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
UNH
3.26
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
UNH’s P/B Ratio of 3.26 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | MRNA | UNH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 16.74 |
| Price-to-Sales Ratio (TTM) | 4.30 | 0.68 |
| Price-to-Book Ratio (MRQ) | 1.08 | 3.26 |
| Price-to-Free Cash Flow Ratio (TTM) | 31.69 | 16.94 |